AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
A phase 1/2 trial of AVZO-1418 in biliary tract cancer, bladder & urothelial cancer and nasopharyngeal carcinoma, run by Avenzo Therapeutics, Inc., now recruiting.
Overview
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) is a phase 1/2 interventional study registered as NCT07038343 by Avenzo Therapeutics, Inc., with 480 participants planned, started 2025-06-04 and due to reach its primary completion in 2030-06. Interventions recorded: AVZO-1418, Combination Agent 1 and Combination Agent 2.
Similar pages
not linked directly; found by shared links- TrialBEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Shares Avenzo Therapeutics, Bladder & urothelial cancer and the tag pipeline.
- TrialAutologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TrialA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.